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Objective of the Study
 To detect the T cell receptor Gamma and Delta gene 
rearrangements in T-cell Acute lymphoblastic 
Leukemia patients in South India
 To Quantitate the Minimal Residual Disease (MRD) 
in follow-up samples of ALL using Real-time PCR
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TCR Gene Rearrangements
 During early T cell differentiation, the germline 
encoded V, D and J gene segments of TCR gene 
complex rearrange
 Each lymphocyte gets a unique V-(D)-J segment that 
codes for the variable domain of TCR molecules
 Combinatorial diversity: By the number of possible 
combinations of V-(D)-J segments
 Junctional diversity: By the random insertion and 
deletion of nucleotides at the junction sites of V-(D)-J 
segments. The junctional regions are unique 
“fingerprint like sequences” different in each lymphoid 
clone 
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Patients and Methods
Patients
 54 T-ALL Patients enrolled for MCP 841treatment 
protocol included for the study
Methodology
10 ml of PB and 2 ml BM collected from the patients 
were used for study
 Isolation of DNA from mononuclear cells
 PCR 
 Heteroduplex analysis
 Sequencing the Homoduplex PCR product to design 
Allele Specific Oligonucleotide primers (ASO)
 Real-time quantitative PCR
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Homo-Heteroduplex Analysis
Monoclonal cells 1      2     3
dS DNA
Monoclonal cells in 
polyclonal background
Denaturation and 
Homoduplex
renaturation of PCR 
product
Heteroduplex
1,2       Clonal
3       PolyClonal
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TCRG gene rearrangements in T-ALL
 TCRG rearranged in 37 of 54 T-ALL cases (68.5%)
 VγI-Jγ1.3/2.3 more commonly rearranged in 29 cases 
(54%)
 VγII-Jγ1.3/2.3 rearranged in 29 cases (26%)
 VγIII-Jγ1.3/2.3 and VγIV-JγI.3/2.3 in 4 cases (7.4%)
 VγI-Jγ1.1/2.1 in 3 cases (5.5%)
 Junctional region sequence of TCRG ranged from 1 
nucleotide to 11 nucleotides (average 7.6 nucleotides) 
 [Ref: Sudhakar et al, American Journal of Hematology 82: 215-221 (2007)]
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TCRD gene rearrangements in T-ALL
 TCRD rearranged in 16 of 54 cases (29.6%)
 Vδ1-Jδ1 rearranged in 9 cases (16.6%)
 Vδ2-Jδ1 and Vδ3-Jδ1 rearranged in one case each 
(1.8%)
 Vδ2-Dδ3 in 5 cases (9.25%) and Dδ2-Dδ3 in 4 cases 
(7.4%)
 Junctional region sequence of TCRD (Vδ1-Jδ1, Vδ2-
Jδ1 and Vδ3-Jδ1) ranged from 14 to 42 nucleotides 
(average 27 nucleotides)
 [Ref: Sudhakar et al, American Journal of Hematology 82: 215-221 (2007)]
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Real-time Quantitative PCR
 Quantitation of DNA using a control gene            
(RNAse P gene)
 Quantitation of MRD
 Diagnosis DNA with almost 100% tumor cell 
involvement was serially diluted (50 ng to 5 ng 
leukemic cells) in 500ng of polyclonal control DNA 
(105 cells) to give final concentrations of 10-1 to10-5
 Serially diluted diagnosis DNA (duplicates) 
subjected to ASO-PCR together with follow-up 
samples (500ng in triplicates) and negative control
 MRD quantities divided by amplifiable DNA.
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Amplification plot and Standard curve
Amplification plot
Ct
Standard curve
1L in 10 N
1L in 102 N
1L in 103 N
1L in 104 N
Cycle number
Log CO
Slope –3.631192
Intercept 38.376797
R2 = 0.962376
N
a
t
u
r
e
 
P
r
e
c
e
d
i
n
g
s
 
:
 
d
o
i
:
1
0
.
1
0
3
8
/
n
p
r
e
.
2
0
1
0
.
5
2
7
4
.
1
 
:
 
P
o
s
t
e
d
 
1
7
 
N
o
v
 
2
0
1
0
MRD Quantitation in ALL patients
RQ-PCR MRD in T-ALL 1
(Genotype VgIII-Jg1)
1
0.0038
0.00028
0.0003
0.0012
0.0001
0.001
0.01
0.1
1
0 I 1 RI 1 M 1 M 2
TREATMENT INTERVAL
M
R
D
RQ-PCR MRD IN CALLA-1
(Genotype VgII-Jg1)
1
0.00013
0.001
0.00037
0.0011
0.0001
0.001
0.01
0.1
1
0 20 DAYS I 1 I 2 M 2
M
R
D
TREATMENT INTERVAL
MRD in T-ALL 3
 (Genotype Vd1-Jd1)
0.74
0.4
0.060.068
1
0.001
0.01
0.1
1
20 days End of RI
1
End of M
2
M 5 M 5 
TREATMENT INTERVAL
M
R
D
RQ-PCR MRD IN T-ALL 2
(Genotype VgII-Jg1) 
1
0.000160.00016
0.00077
0.0056
0.0001
0.001
0.01
0.1
1
0 AFTER 20
DAYS
I 1 I 2 M 1
TREATMENT INTERVAL
M
R
D
N
a
t
u
r
e
 
P
r
e
c
e
d
i
n
g
s
 
:
 
d
o
i
:
1
0
.
1
0
3
8
/
n
p
r
e
.
2
0
1
0
.
5
2
7
4
.
1
 
:
 
P
o
s
t
e
d
 
1
7
 
N
o
v
 
2
0
1
0
Conclusion
 TCRG rearrangements were detected in 68.5% and 
TCRD in 29.6% of the patients
 After Induction therapy, in 3 of the 4 patients lesser 
than 2 leukemic cells in 103 normal cells were present 
and those patients are in clinical and hematological 
remission
 MRD quantitation with more number of samples 
before and after treatment are required to risk stratify 
the patients
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